Sign in
Taking people in United StatesPhase 2

Tumor gene screening to assign drug combinations in advanced solid tumors

Screens advanced solid tumors for gene changes to assign drugs.

Key facts

Who runs it
National Cancer Institute (NCI)
Where
‘Aiea, ‘Ewa Beach, Abilene, Albuquerque, Allentown, Altoona, Anaconda, Anchorage, Ankeny, Ann Arbor, Appleton, Arroyo Grande, Asheboro, Ashland, Athens, Augusta, Aurora, Aventura, Avon, Baltimore, Barrington, Battle Creek, Beachwood, Bellevue, Belpre, Bemidji, Berlin, Bethesda, Bethlehem, Billings, Birmingham, Bismarck, Bloomington, Boiling Springs, Boise, Boston, Bozeman, Brewer, Brighton, Bristol, Bryn Mawr, Buffalo, Burlington, Caldwell, Canton, Cape Girardeau, Carmichael, Carterville, Carthage, Cedar Rapids, Centerville, Centralia, Charleston, Charlottesville, Chelsea, Chesterfield, Chicago, Chillicothe, Cincinnati, City of Saint Peters, Cleveland, Clinton, Coeur d'Alene, Collierville, Columbia, Columbus, Commack, Coon Rapids, Coral Gables, Creve Coeur, Crown Point, Crystal Lake, Cumberland, Dallas, Danville, Dayton, Dearborn, Decatur, Deer River, Deerfield Beach, DeKalb, Delaware, Des Moines, Dixon, Downers Grove, Dublin, Duluth, Durham, Easley, East Stroudsburg, Eau Claire, Edina, Edmonds, Effingham, Elgin, Elk Grove, Encinitas, Erie, Escanaba, Eureka, Evanston, Fairfax, Falls Church, Fargo, Farmington, Farmington Hills, Findlay, Flemington, Flint, Fort Collins, Fort Lauderdale, Franklin, Fruitland, Gainesville, Galesburg, Geneva, Germantown, Glenview, Goldsboro, Goodyear, Grafton, Grand Rapids, Grayslake, Great Falls, Greeley, Green Bay, Greensboro, Greensburg, Greenville, Greer, Grenada, Grove City, Gulfport, Harrison, Harvey, Hazel Crest, Hazleton, Hibbing, High Point, Highland Park, Honolulu, Houston, Huntington, Issaquah, Jacksonville, Janesville, Johnson City, Jonesboro, Kalamazoo, Kalispell, Kenosha, Kettering, Kewanee, Kingman, Kingsport, La Crosse, La Jolla, Lacey, Lake Forest, Lakewood, Lancaster, Lansing, Las Vegas, Lexington, Libertyville, Livingston, Livonia, Long Branch, Los Angeles, Loveland, Lubbock, Macomb, Madison, Manistique, Mansfield, Maple Grove, Maplewood, Marinette, Marion, Marshfield, Martinez, Marysville, Mattoon, Mayfield Heights, Maywood, Mechanicsburg, Media, Memphis, Mentor, Meridian, Metairie, Miami, Michigan City, Middleburg Heights, Middletown, Milwaukee, Mineola, Minneapolis, Minocqua, Missoula, Mobile, Monroeville, Morgantown, Mount Vernon, Mukwonago, Muskegon, Nampa, Nashville, Nassau Bay, Neenah, New Albany, New Brunswick, New Lenox, New London, New Orleans, New Richmond, New York, Newark, Newberg, Newnan, Niles, Normal, North Miami, Norton Shores, O'Fallon, Oak Lawn, Oconomowoc, Oconto Falls, Oklahoma City, Omaha, Ontario, Orange, Oregon City, Orland Park, Oshkosh, Ottawa, Oxford, Paducah, Palo Alto, Paoli, Park Ridge, Pekin, Pennington, Peoria, Perrysburg, Peru, Philadelphia, Phoenix, Pickerington, Pittsburgh, Plantation, Pontiac, Portland, Portsmouth, Post Falls, Princeton, Providence, Racine, Raleigh, Rapid City, Reed City, Reidsville, Reno, Renton, Rice Lake, Richmond, Roanoke, Rochester, Rockford, Rocklin, Rolla, Royal Oak, Sacramento, Saginaw, Saint Joseph, Saint Louis Park, Saint Paul, Sainte Genevieve, San Diego, San Francisco, Sandpoint, Sandstone, Santa Monica, Sayre, Scarborough, Seattle, Seneca, Sewell, Shawano, Sheboygan, Shiloh, Sioux Falls, Somerville, South Bend, South Hill, South Portland, Southhaven, Springfield, St Louis, Stevens Point, Stoneham, Sturgeon Bay, Sugar Land, Sullivan, Summit, Syracuse, Tawas City, Temple, The Bronx, The Woodlands, Toledo, Toms River, Traverse City, Troy, Twin Falls, Two Rivers, Urbana, Virginia, Walla Walla, Walnut Creek, Warrenville, Washington, Waukee, Waukesha, Waupaca, Wauwatosa, West Allis, West Branch, Westerville, Weston, Whittier, Willow Grove, Winston-Salem, Woodland, Wynnewood, Wyoming, Yakima, Youngstown, Ypsilanti, Zanesville, and Zion, United StatesSee the 480 sitesAlso in 1 other country, 4 sites
Trial code
Registry title
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Status
Recruiting
Phase
Phase 2
People taking part
2,900 people, planned
Started
7 Apr 2023
Expected to end
1 Jul 2030
Type of study
Interventional, 20 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Alpelisib
  • Binimetinib
  • Biopsy Procedure
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Bone Scan
  • Computed Tomography
  • Echocardiography Test
  • Fluorouracil
  • Fulvestrant
  • Ipatasertib
  • Leucovorin
  • Magnetic Resonance Imaging
  • Multigated Acquisition Scan
  • Mutation Carrier Screening
  • Neratinib Maleate
  • Nilotinib Hydrochloride Monohydrate
  • Olaparib
  • Oxaliplatin
  • Paclitaxel
  • Palbociclib
  • Panitumumab
  • Positron Emission Tomography
  • Selumetinib Sulfate
  • Sotorasib
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with solid tumors that have spread nearby or elsewhere in the body. The cancer must have worsened on standard treatment, or have no standard treatment that prolongs survival.

Age
Adults 18 years and older, and also people under 18 who have stored tumor tissue available.
Sex
All sexes can join.
Disease stage
Locally advanced or advanced solid tumors needing treatment, with disease that can be measured.
Earlier treatment
The cancer must have progressed on at least one line of standard systemic therapy, or have no standard treatment shown to prolong overall survival.
Biomarker or test result
Tumor gene sequencing results from an NCI credentialed Designated Laboratory must be available.

Main reasons for not taking part

  • No measurable disease
  • ECOG performance status above 2, or Lansky or Karnofsky status below 50%
  • No sequencing results from an NCI credentialed Designated Laboratory
  • Not seen by the enrolling provider as potentially able to join a ComboMATCH Treatment Trial
  • No biopsiable tumor and no archival tumor tissue available

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patient must have measurable disease
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of >= 50% or Karnofsky performance status of >= 50%
  • Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider
  • All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL)
  • Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria:; Patients must have progressed on at least one line of standard systemic therapy OR; Patients whose disease has no standard treatment that has been shown to prolong overall survival
  • Patient must meet one of the following requirements:; Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial OR; Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:; Tissue must have been collected within 12 months prior to registration to the EAY191 Registration Trial; Patient must not have had a Response Evaluation Criteria in Solid Tumors (RECIST) response (complete response [CR] or partial response [PR]) to any intervening therapy after collection of the tissue; Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available OR; Patients under 18 years old must confirm availability of an archival tumor tissue specimen for submission for research if patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:; Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available; NOTE: See specific ComboMATCH Treatment Trial protocol for tissue collection and management instructions. Performance of the mandatory research biopsy or submission of pre-trial formalin-fixed paraffin-embedded (FFPE) and collection and submission of the blood specimens for the integrated studies will be performed under the consent authority of the specific treatment trial protocol to which the patient is registered. No procedures to collect specimens for research only are to be performed for patients registered to the EAY191 Registration Trial only
  • NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If patient is found to not be eligible for the assigned ComboMATCH Treatment Trial, indication of ineligibility will trigger re-evaluation and potential assignment to another Treatment Trial

Where in United States

Also in 1 other country, 4 sites

  • Hawaii Cancer Care - Westridge‘Aiea, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • Pali Momi Medical Center‘Aiea, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • The Queen's Medical Center - West Oahu‘Ewa Beach, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • Hendrick Medical CenterAbilene, United StatesContact: Jose C. Velasco Di Domenico (principal investigator)Taking people
  • University of New Mexico Cancer CenterAlbuquerque, United StatesContact: Bernard Tawfik (principal investigator)Taking people
  • Lehigh Valley Hospital-Cedar CrestAllentown, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • UPMC AltoonaAltoona, United StatesContact: Adam M. Brufsky (principal investigator)Taking people
  • Community Hospital of AnacondaAnaconda, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Alaska Women's Cancer CareAnchorage, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • University of Michigan Rogel Cancer CenterAnn Arbor, United StatesContact: Anne F. Schott (principal investigator)Taking people
  • ThedaCare Regional Cancer CenterAppleton, United StatesContact: Matthias Weiss (principal investigator)Taking people
  • ThedaCare Regional Medical Center - AppletonAppleton, United StatesContact: Matthias Weiss (principal investigator)Taking people
  • PCR OncologyArroyo Grande, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • Cone Health MedCenter AsheboroAsheboro, United StatesContact: Vinay K. Gudena (principal investigator)Taking people
  • Duluth Clinic AshlandAshland, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • OhioHealth O'Bleness HospitalAthens, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Harold Alfond Center for Cancer CareAugusta, United StatesContact: Leslie S. Bradford (principal investigator)Taking people
  • UCHealth University of Colorado HospitalAurora, United StatesContact: Bradley R. Corr (principal investigator)Taking people
  • UM Sylvester Comprehensive Cancer Center at AventuraAventura, United StatesContact: Chukwuemeka (Emeka) V. Ikpeazu (principal investigator)Taking people
  • UH Seidman Cancer Center at UH Avon Health CenterAvon, United StatesContact: Alberto J. Montero (principal investigator)Taking people
  • University of Maryland/Greenebaum Cancer CenterBaltimore, United StatesContact: Ranee Mehra (principal investigator)Taking people
  • Advocate Good Shepherd HospitalBarrington, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Bronson Battle CreekBattle Creek, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • UHHS-Chagrin Highlands Medical CenterBeachwood, United StatesContact: Alberto J. Montero (principal investigator)Taking people
  • Nebraska Medicine-BellevueBellevue, United StatesNo longer taking part
  • Strecker Cancer Center-BelpreBelpre, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Sanford Joe Lueken Cancer CenterBemidji, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • ThedaCare Cancer Care - BerlinBerlin, United StatesContact: Matthias Weiss (principal investigator)Taking people
  • National Institutes of Health Clinical CenterBethesda, United StatesContact: A P. Chen (principal investigator)Taking people
  • Walter Reed National Military Medical CenterBethesda, United StatesContact: Jeremy G. Perkins (principal investigator)Taking people
  • Lehigh Valley Hospital - MuhlenbergBethlehem, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Billings Clinic Cancer CenterBillings, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • University of Alabama at Birmingham Cancer CenterBirmingham, United StatesContact: Rebecca C. Arend (principal investigator)Taking people
  • Sanford Bismarck Medical CenterBismarck, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Illinois CancerCare-BloomingtonBloomington, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Prisma Health Cancer Institute - SpartanburgBoiling Springs, United StatesContact: Ki Y. Chung (principal investigator)Taking people
  • Saint Alphonsus Cancer Care Center-BoiseBoise, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Saint Luke's Cancer Institute - BoiseBoise, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Geoffrey I. Shapiro (principal investigator)Taking people
  • Tufts Medical CenterBoston, United StatesContact: Francis W. Nugent (principal investigator)Taking people
  • Beth Israel Deaconess Medical CenterBoston, United StatesNo longer taking part
  • Bozeman Health Deaconess HospitalBozeman, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Lafayette Family Cancer Center-EMMCBrewer, United StatesContact: Sarah J. Sinclair (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology - BrightonBrighton, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Trinity Health Medical Center - BrightonBrighton, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • University of Michigan - Brighton Center for Specialty CareBrighton, United StatesContact: Anne F. Schott (principal investigator)Taking people
  • Ballad Health Cancer Care - BristolBristol, United StatesContact: Asheesh Shipstone (principal investigator)Taking people
  • Bryn Mawr HospitalBryn Mawr, United StatesContact: Paul B. Gilman (principal investigator)Taking people
  • Roswell Park Cancer InstituteBuffalo, United StatesContact: Ellis G. Levine (principal investigator)Taking people
  • Aurora Cancer Care-Southern Lakes VLCCBurlington, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Cone Health Cancer Center at Alamance RegionalBurlington, United StatesContact: Vinay K. Gudena (principal investigator)Taking people
  • Saint Alphonsus Cancer Care Center-CaldwellCaldwell, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Aultman Health FoundationCanton, United StatesContact: Sunitha Vemulapalli (principal investigator)Taking people
  • Illinois CancerCare-CantonCanton, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology - CantonCanton, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Trinity Health Medical Center - CantonCanton, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Saint Francis Medical CenterCape Girardeau, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Mercy Cancer Center - CarmichaelCarmichael, United StatesContact: Loretta J. Nastoupil (principal investigator)Taking people
  • Mercy San Juan Medical CenterCarmichael, United StatesContact: Loretta J. Nastoupil (principal investigator)Taking people
  • SIH Cancer InstituteCarterville, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Illinois CancerCare-CarthageCarthage, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Mercy HospitalCedar Rapids, United StatesContact: Deborah W. Wilbur (principal investigator)Taking people
  • Oncology Associates at Mercy Medical CenterCedar Rapids, United StatesContact: Deborah W. Wilbur (principal investigator)Taking people
  • Miami Valley Hospital SouthCenterville, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Centralia Oncology ClinicCentralia, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Vandalia Health/CAMC Institute for Academic MedicineCharleston, United StatesContact: Ahmed A. Khalid (principal investigator)Taking people
  • University of Virginia Cancer CenterCharlottesville, United StatesContact: Matthew J. Reilley (principal investigator)Taking people
  • Chelsea HospitalChelsea, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Saint Luke's HospitalChesterfield, United StatesContact: Meera Rana (principal investigator)Taking people
  • Advocate Illinois Masonic Medical CenterChicago, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • John H Stroger Jr Hospital of Cook CountyChicago, United StatesContact: Deimante M. Tamkus (principal investigator)Taking people
  • Mount Sinai Hospital Medical CenterChicago, United StatesContact: Pam G. Khosla (principal investigator)Taking people
  • Northwestern UniversityChicago, United StatesContact: Devalingam Mahalingam (principal investigator)Taking people
  • University of Chicago Comprehensive Cancer CenterChicago, United StatesContact: Ardaman Shergill (principal investigator)Taking people
  • University of IllinoisChicago, United StatesContact: Ryan Nguyen (principal investigator)Taking people
  • Adena Regional Medical CenterChillicothe, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Good Samaritan Hospital - CincinnatiCincinnati, United StatesContact: Loretta J. Nastoupil (principal investigator)Taking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesNo longer taking part
  • Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, United StatesContact: Nusayba Bagegni (principal investigator)Taking people
  • Case Western Reserve UniversityCleveland, United StatesContact: Alberto J. Montero (principal investigator)Taking people
  • Cleveland Clinic Cancer Center/Fairview HospitalCleveland, United StatesNo longer taking part
  • Cleveland Clinic FoundationCleveland, United StatesNo longer taking part
  • Southeastern Medical Oncology Center-ClintonClinton, United StatesContact: Samer S. Kasbari (principal investigator)Taking people
  • Kootenai Health - Coeur d'AleneCoeur d'Alene, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-ColliervilleCollierville, United StatesContact: Andrew J. Benefield (principal investigator)Taking people
  • Prisma Health Richland HospitalColumbia, United StatesContact: Ki Y. Chung (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-Golden TriangleColumbus, United StatesContact: Andrew J. Benefield (principal investigator)Taking people
  • Columbus Oncology and Hematology Associates IncColumbus, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Doctors HospitalColumbus, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Grant Medical CenterColumbus, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Mount Carmel East HospitalColumbus, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Floor Backes (principal investigator)Taking people
  • Riverside Methodist HospitalColumbus, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • The Mark H Zangmeister CenterColumbus, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Memorial Sloan Kettering CommackCommack, United StatesContact: Alison M. Schram (principal investigator)Taking people
  • Mercy HospitalCoon Rapids, United StatesContact: David M. King (principal investigator)Taking people
  • UM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables, United StatesContact: Chukwuemeka (Emeka) V. Ikpeazu (principal investigator)Taking people
  • Siteman Cancer Center at West County HospitalCreve Coeur, United StatesContact: Nusayba Bagegni (principal investigator)Taking people
  • UChicago Medicine Northwest IndianaCrown Point, United StatesContact: Ardaman Shergill (principal investigator)Taking people
  • AMG Crystal Lake - OncologyCrystal Lake, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • UPMC Western MarylandCumberland, United StatesContact: Adam M. Brufsky (principal investigator)Taking people
  • UT Southwestern/Simmons Cancer Center-DallasDallas, United StatesContact: Devin E. Jones (principal investigator)Taking people
  • Carle at The RiverfrontDanville, United StatesContact: Tanmay Sahai (principal investigator)Taking people
  • Miami Valley HospitalDayton, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Miami Valley Hospital NorthDayton, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Premier Blood and Cancer CenterDayton, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Dayton Physician LLC - EnglewoodDayton, United StatesNo longer taking part
  • Corewell Health Dearborn HospitalDearborn, United StatesContact: Dana Zakalik (principal investigator)Taking people
  • Cancer Care Specialists of Illinois - DecaturDecatur, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Decatur Memorial HospitalDecatur, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Essentia Health - Deer River ClinicDeer River, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • UM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach, United StatesContact: Chukwuemeka (Emeka) V. Ikpeazu (principal investigator)Taking people
  • Northwestern Medicine Cancer Center KishwaukeeDeKalb, United StatesContact: Devalingam Mahalingam (principal investigator)Taking people
  • Delaware Health Center-Grady Cancer CenterDelaware, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Grady Memorial HospitalDelaware, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Mercy Medical Center - Des MoinesDes Moines, United StatesContact: Richard L. Deming (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Illinois CancerCare-DixonDixon, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Advocate Good Samaritan HospitalDowners Grove, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Columbus Oncology and Hematology AssociatesDublin, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Dublin Methodist HospitalDublin, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Epic Care-DublinDublin, United StatesNo longer taking part
  • Essentia Health Cancer CenterDuluth, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Duke University Medical CenterDurham, United StatesContact: Angeles A. Secord (principal investigator)Taking people
  • Prisma Health Cancer Institute - EasleyEasley, United StatesContact: Ki Y. Chung (principal investigator)Taking people
  • Pocono Medical CenterEast Stroudsburg, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Marshfield Medical Center-EC Cancer CenterEau Claire, United StatesContact: Adedayo A. Onitilo (principal investigator)Taking people
  • Fairview Southdale HospitalEdina, United StatesContact: David M. King (principal investigator)Taking people
  • Minnesota Oncology - EdinaEdina, United StatesContact: David M. King (principal investigator)Taking people
  • Swedish Cancer Institute-EdmondsEdmonds, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Carle Physician Group-EffinghamEffingham, United StatesContact: Tanmay Sahai (principal investigator)Taking people
  • Crossroads Cancer CenterEffingham, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Advocate Sherman HospitalElgin, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Mercy Cancer Center - Elk GroveElk Grove, United StatesContact: Loretta J. Nastoupil (principal investigator)Taking people
  • UC San Diego Health System - EncinitasEncinitas, United StatesContact: Peter Vu (principal investigator)Taking people
  • UPMC Hillman Cancer Center ErieErie, United StatesContact: Adam M. Brufsky (principal investigator)Taking people
  • OSF Saint Francis Hospital and Medical GroupEscanaba, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Illinois CancerCare-EurekaEureka, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • NorthShore University HealthSystem-Evanston HospitalEvanston, United StatesContact: Mary T. Jenkins Vogel (principal investigator)Taking people
  • Inova Schar Cancer InstituteFairfax, United StatesContact: Timothy L. Cannon (principal investigator)Taking people
  • Inova Fairfax HospitalFalls Church, United StatesContact: Timothy L. Cannon (principal investigator)Taking people
  • Sanford Broadway Medical CenterFargo, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Sanford Roger Maris Cancer CenterFargo, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Parkland Health Center - FarmingtonFarmington, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Corewell Health Farmington Hills HospitalFarmington Hills, United StatesNo longer taking part
  • Armes Family Cancer CenterFindlay, United StatesNo longer taking part
  • Hunterdon Medical CenterFlemington, United StatesContact: Myron E. Bednar (principal investigator)Taking people
  • Cancer Hematology Centers - FlintFlint, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Genesys Hurley Cancer InstituteFlint, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Hurley Medical CenterFlint, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Genesee Hematology Oncology PCFlint, United StatesNo longer taking part
  • Cancer Care and Hematology-Fort CollinsFort Collins, United StatesContact: Bradley R. Corr (principal investigator)Taking people
  • Poudre Valley HospitalFort Collins, United StatesContact: Bradley R. Corr (principal investigator)Taking people
  • Broward Health Medical CenterFort Lauderdale, United StatesNo longer taking part
  • Atrium Medical Center-Middletown Regional HospitalFranklin, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Dayton Physicians LLC-AtriumFranklin, United StatesNo longer taking part
  • Saint Luke's Cancer Institute - FruitlandFruitland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • UF Health Cancer Institute - GainesvilleGainesville, United StatesContact: Thomas J. George (principal investigator)Taking people
  • Illinois CancerCare-GalesburgGalesburg, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Northwestern Medicine Cancer Center DelnorGeneva, United StatesContact: Devalingam Mahalingam (principal investigator)Taking people
  • Aurora Health Care Germantown Health CenterGermantown, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • NorthShore University HealthSystem-Glenbrook HospitalGlenview, United StatesContact: Mary T. Jenkins Vogel (principal investigator)Taking people
  • Northwestern Medicine Glenview Outpatient CenterGlenview, United StatesContact: Devalingam Mahalingam (principal investigator)Taking people
  • Southeastern Medical Oncology Center-GoldsboroGoldsboro, United StatesContact: Samer S. Kasbari (principal investigator)Taking people
  • CTCA at Western Regional Medical CenterGoodyear, United StatesContact: Sagun Shrestha (principal investigator)Taking people
  • Aurora Cancer Care-GraftonGrafton, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Corewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Trinity Health Grand Rapids HospitalGrand Rapids, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Northwestern Medicine Grayslake Outpatient CenterGrayslake, United StatesContact: Devalingam Mahalingam (principal investigator)Taking people
  • Benefis Sletten Cancer InstituteGreat Falls, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • UCHealth Greeley HospitalGreeley, United StatesContact: Bradley R. Corr (principal investigator)Taking people
  • Aurora BayCare Medical CenterGreen Bay, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center Green BayGreen Bay, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Cone Health Cancer CenterGreensboro, United StatesContact: Vinay K. Gudena (principal investigator)Taking people
  • Cone Health Cancer Center at Drawbridge ParkwayGreensboro, United StatesContact: Vinay K. Gudena (principal investigator)Taking people
  • UPMC Cancer Centers - Arnold Palmer PavilionGreensburg, United StatesContact: Adam M. Brufsky (principal investigator)Taking people
  • BI-LO Charities Children's Cancer CenterGreenville, United StatesContact: Ki Y. Chung (principal investigator)Taking people
  • Miami Valley Cancer Care and InfusionGreenville, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Prisma Health Cancer Institute - ButternutGreenville, United StatesContact: Ki Y. Chung (principal investigator)Taking people
  • Prisma Health Cancer Institute - EastsideGreenville, United StatesContact: Ki Y. Chung (principal investigator)Taking people
  • Prisma Health Cancer Institute - FarisGreenville, United StatesContact: Ki Y. Chung (principal investigator)Taking people
  • Saint Francis Cancer CenterGreenville, United StatesContact: Stephen H. Dyar (principal investigator)Taking people
  • Saint Francis HospitalGreenville, United StatesContact: Stephen H. Dyar (principal investigator)Taking people
  • Prisma Health Cancer Institute - GreerGreer, United StatesContact: Ki Y. Chung (principal investigator)Taking people
  • Baptist Cancer Center-GrenadaGrenada, United StatesContact: Andrew J. Benefield (principal investigator)Taking people
  • Zangmeister Center Grove CityGrove City, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Gulfport Memorial HospitalGulfport, United StatesNo longer taking part
  • Memorial Sloan Kettering WestchesterHarrison, United StatesContact: Alison M. Schram (principal investigator)Taking people
  • Ingalls Memorial HospitalHarvey, United StatesContact: James A. Wallace (principal investigator)Taking people
  • Advocate South Suburban HospitalHazel Crest, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Lehigh Valley Hospital-HazletonHazleton, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Essentia Health Hibbing ClinicHibbing, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Hayworth Cancer CenterHigh Point, United StatesContact: Anna Kuan-Celarier (principal investigator)Taking people
  • NorthShore University HealthSystem-Highland Park HospitalHighland Park, United StatesContact: Mary T. Jenkins Vogel (principal investigator)Taking people
  • Hawaii Cancer Care Inc - Waterfront PlazaHonolulu, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • Kapiolani Medical Center for Women and ChildrenHonolulu, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • Queen's Cancer Cenrer - POB IHonolulu, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • Queen's Cancer Center - KuakiniHonolulu, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • Queen's Medical CenterHonolulu, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • Straub Clinic and HospitalHonolulu, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • University of Hawaii Cancer CenterHonolulu, United StatesContact: Jeffrey L. Berenberg (principal investigator)Taking people
  • Lyndon Baines Johnson General HospitalHouston, United StatesContact: Funda Meric-Bernstam (principal investigator)Taking people
  • UT MD Anderson Cancer CenterHouston, United StatesContact: Funda Meric-Bernstam (principal investigator)Taking people
  • Houston Methodist HospitalHouston, United StatesNo longer taking part
  • Houston Methodist West HospitalHouston, United StatesNo longer taking part
  • Methodist Willowbrook HospitalHouston, United StatesNo longer taking part
  • Edwards Comprehensive Cancer CenterHuntington, United StatesContact: Toni O. Pacioles (principal investigator)Taking people
  • Swedish Cancer Institute-IssaquahIssaquah, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Mayo Clinic in FloridaJacksonville, United StatesContact: Aaron S. Mansfield (principal investigator)Taking people
  • Southeastern Medical Oncology Center-JacksonvilleJacksonville, United StatesContact: Samer S. Kasbari (principal investigator)Taking people
  • Mercyhealth Hospital and Cancer Center - JanesvilleJanesville, United StatesContact: Emily G. Robinson (principal investigator)Taking people
  • Regional Cancer Center at Johnson City Medical CenterJohnson City, United StatesContact: Asheesh Shipstone (principal investigator)Taking people
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro, United StatesContact: Andrew J. Benefield (principal investigator)Taking people
  • Beacon KalamazooKalamazoo, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Beacon Kalamazoo Cancer CenterKalamazoo, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Bronson Methodist HospitalKalamazoo, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • West Michigan Cancer CenterKalamazoo, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Logan Health Medical CenterKalispell, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Aurora Cancer Care-Kenosha SouthKenosha, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Kettering Medical CenterKettering, United StatesContact: Howard M. Gross (principal investigator)Taking people
  • Greater Dayton Cancer CenterKettering, United StatesNo longer taking part
  • Illinois CancerCare-Kewanee ClinicKewanee, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Kingman Regional Medical CenterKingman, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • Ballad Health Cancer Care - KingsportKingsport, United StatesContact: Asheesh Shipstone (principal investigator)Taking people
  • Gundersen Lutheran Medical CenterLa Crosse, United StatesContact: Kurt Oettel (principal investigator)Taking people
  • UC San Diego Moores Cancer CenterLa Jolla, United StatesContact: Peter Vu (principal investigator)Taking people
  • Providence Regional Cancer System-LaceyLacey, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Northwestern Medicine Lake Forest HospitalLake Forest, United StatesContact: Devalingam Mahalingam (principal investigator)Taking people
  • Monmouth Medical Center Southern CampusLakewood, United StatesContact: Patrick M. Boland (principal investigator)Taking people
  • Fairfield Medical CenterLancaster, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • University of Michigan Health - Sparrow LansingLansing, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Alliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • OptumCare Cancer Care at CharlestonLas Vegas, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • Summerlin Hospital Medical CenterLas Vegas, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • OptumCare Cancer Care at Fort ApacheLas Vegas, United StatesNo longer taking part
  • CommonSpirit Saint Joseph Medical Center - East LexingtonLexington, United StatesContact: Loretta J. Nastoupil (principal investigator)Taking people
  • University of Kentucky/Markey Cancer CenterLexington, United StatesContact: Susanne M. Arnold (principal investigator)Taking people
  • AMG Libertyville - OncologyLibertyville, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Condell Memorial HospitalLibertyville, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Cooperman Barnabas Medical CenterLivingston, United StatesContact: Patrick M. Boland (principal investigator)Taking people
  • Trinity Health Saint Mary Mercy Livonia HospitalLivonia, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Monmouth Medical CenterLong Branch, United StatesContact: Patrick M. Boland (principal investigator)Taking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Omid Hamid (principal investigator)Taking people
  • The Angeles Clinic and Research Institute - West Los Angeles OfficeLos Angeles, United StatesContact: Omid Hamid (principal investigator)Taking people
  • Medical Center of the RockiesLoveland, United StatesContact: Bradley R. Corr (principal investigator)Taking people
  • Covenant Medical Center-LakesideLubbock, United StatesNo longer taking part
  • Henry Ford Saint John Hospital - Macomb MedicalMacomb, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Illinois CancerCare-MacombMacomb, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison, United StatesContact: Nataliya V. Uboha (principal investigator)Taking people
  • University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Nataliya V. Uboha (principal investigator)Taking people
  • Schoolcraft Memorial HospitalManistique, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • OhioHealth Mansfield HospitalMansfield, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Fairview Clinics and Surgery Center Maple GroveMaple Grove, United StatesContact: David M. King (principal investigator)Taking people
  • Saint John's Hospital - HealtheastMaplewood, United StatesContact: David M. King (principal investigator)Taking people
  • Aurora Bay Area Medical Group-MarinetteMarinette, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • OhioHealth Marion General HospitalMarion, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Marshfield Medical Center-MarshfieldMarshfield, United StatesContact: Adedayo A. Onitilo (principal investigator)Taking people
  • Contra Costa Regional Medical CenterMartinez, United StatesNo longer taking part
  • Memorial HospitalMarysville, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Carle Physician Group-Mattoon/CharlestonMattoon, United StatesContact: Tanmay Sahai (principal investigator)Taking people
  • Hillcrest Hospital Cancer CenterMayfield Heights, United StatesNo longer taking part
  • Loyola University Medical CenterMaywood, United StatesContact: Nan Sethakorn (principal investigator)Taking people
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer PavilionMechanicsburg, United StatesContact: Adam M. Brufsky (principal investigator)Taking people
  • Riddle Memorial HospitalMedia, United StatesContact: Paul B. Gilman (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-MemphisMemphis, United StatesContact: Andrew J. Benefield (principal investigator)Taking people
  • UH Seidman Cancer Center at Lake Health Mentor CampusMentor, United StatesContact: Alberto J. Montero (principal investigator)Taking people
  • Saint Luke's Cancer Institute - MeridianMeridian, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • East Jefferson General HospitalMetairie, United StatesNo longer taking part
  • UM Sylvester Comprehensive Cancer Center at KendallMiami, United StatesContact: Chukwuemeka (Emeka) V. Ikpeazu (principal investigator)Taking people
  • University of Miami Miller School of Medicine-Sylvester Cancer CenterMiami, United StatesContact: Chukwuemeka (Emeka) V. Ikpeazu (principal investigator)Taking people
  • Woodland Cancer Care CenterMichigan City, United StatesContact: William H. Bae (principal investigator)Taking people
  • UH Seidman Cancer Center at Southwest General HospitalMiddleburg Heights, United StatesNo longer taking part
  • Memorial Sloan Kettering MonmouthMiddletown, United StatesContact: Alison M. Schram (principal investigator)Taking people
  • Aurora Cancer Care-MilwaukeeMilwaukee, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Aurora Saint Luke's Medical CenterMilwaukee, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Aurora Sinai Medical CenterMilwaukee, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • NYU Langone Hospital - Long IslandMineola, United StatesContact: Kristen R. Spencer (principal investigator)Taking people
  • Abbott-Northwestern HospitalMinneapolis, United StatesContact: David M. King (principal investigator)Taking people
  • Marshfield Medical Center - MinocquaMinocqua, United StatesContact: Adedayo A. Onitilo (principal investigator)Taking people
  • Community Medical CenterMissoula, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • University of South Alabama Mitchell Cancer InstituteMobile, United StatesContact: Ahmed Abdalla (principal investigator)Taking people
  • UPMC Hillman Cancer Center - MonroevilleMonroeville, United StatesContact: Adam M. Brufsky (principal investigator)Taking people
  • West Virginia University HealthcareMorgantown, United StatesContact: Mohammed Almubarak (principal investigator)Taking people
  • Knox Community HospitalMount Vernon, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • SSM Health Good SamaritanMount Vernon, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • ProHealth D N Greenwald CenterMukwonago, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • Trinity Health Muskegon HospitalMuskegon, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Saint Alphonsus Cancer Care Center-NampaNampa, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Saint Luke's Cancer Institute - NampaNampa, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Vanderbilt Breast Center at One Hundred OaksNashville, United StatesContact: Jennifer H. Choe (principal investigator)Taking people
  • Vanderbilt University/Ingram Cancer CenterNashville, United StatesContact: Jennifer H. Choe (principal investigator)Taking people
  • Houston Methodist Saint John HospitalNassau Bay, United StatesNo longer taking part
  • ThedaCare Regional Medical Center - NeenahNeenah, United StatesContact: Matthias Weiss (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-Union CountyNew Albany, United StatesContact: Andrew J. Benefield (principal investigator)Taking people
  • Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesContact: Patrick M. Boland (principal investigator)Taking people
  • UC Comprehensive Cancer Center at Silver CrossNew Lenox, United StatesContact: Ardaman Shergill (principal investigator)Taking people
  • ThedaCare Cancer Care - New LondonNew London, United StatesContact: Matthias Weiss (principal investigator)Taking people
  • Ochsner Medical Center JeffersonNew Orleans, United StatesContact: John T. Cole (principal investigator)Taking people
  • University Medical Center New OrleansNew Orleans, United StatesNo longer taking part
  • Cancer Center of Western WisconsinNew Richmond, United StatesContact: David M. King (principal investigator)Taking people
  • Laura and Isaac Perlmutter Cancer Center at NYU LangoneNew York, United StatesContact: Kristen R. Spencer (principal investigator)Taking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Alison M. Schram (principal investigator)Taking people
  • Mount Sinai HospitalNew York, United StatesContact: Deborah B. Doroshow (principal investigator)Taking people
  • Helen F Graham Cancer CenterNewark, United StatesContact: Gregory A. Masters (principal investigator)Taking people
  • Licking Memorial HospitalNewark, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Medical Oncology Hematology Consultants PANewark, United StatesContact: Gregory A. Masters (principal investigator)Taking people
  • Providence Newberg Medical CenterNewberg, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • CTCA at Southeastern Regional Medical CenterNewnan, United StatesNo longer taking part
  • Corewell Health Lakeland Hospitals - Niles HospitalNiles, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Carle BroMenn Medical CenterNormal, United StatesContact: Tanmay Sahai (principal investigator)Taking people
  • Carle Cancer Institute NormalNormal, United StatesContact: Tanmay Sahai (principal investigator)Taking people
  • University of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami, United StatesContact: Chukwuemeka (Emeka) V. Ikpeazu (principal investigator)Taking people
  • Cancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Cancer Care Center of O'FallonO'Fallon, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Advocate Christ Medical CenterOak Lawn, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • ProHealth Oconomowoc Memorial HospitalOconomowoc, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at Oconto FallsOconto Falls, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Lauren E. Dockery (principal investigator)Taking people
  • Nebraska Medicine-Village PointeOmaha, United StatesNo longer taking part
  • University of Nebraska Medical CenterOmaha, United StatesNo longer taking part
  • Saint Alphonsus Cancer Care Center-OntarioOntario, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Children's Hospital of Orange CountyOrange, United StatesContact: Elyssa M. Rubin (principal investigator)Taking people
  • Saint Joseph Hospital - OrangeOrange, United StatesContact: Timothy E. Byun (principal investigator)Taking people
  • Providence Willamette Falls Medical CenterOregon City, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Northwestern Medicine Orland ParkOrland Park, United StatesContact: Devalingam Mahalingam (principal investigator)Taking people
  • University of Chicago Medicine-Orland ParkOrland Park, United StatesContact: Ardaman Shergill (principal investigator)Taking people
  • ThedaCare Cancer Care - OshkoshOshkosh, United StatesContact: Matthias Weiss (principal investigator)Taking people
  • Vince Lombardi Cancer Clinic - OshkoshOshkosh, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Illinois CancerCare-Ottawa ClinicOttawa, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-OxfordOxford, United StatesContact: Andrew J. Benefield (principal investigator)Taking people
  • Mercy Health - Paducah Cancer CenterPaducah, United StatesNo longer taking part
  • Stanford Cancer Institute Palo AltoPalo Alto, United StatesContact: James M. Ford (principal investigator)Taking people
  • VA Palo Alto Health Care SystemPalo Alto, United StatesContact: Harlan A. Pinto (principal investigator)Taking people
  • Paoli Memorial HospitalPaoli, United StatesContact: Paul B. Gilman (principal investigator)Taking people
  • Advocate Lutheran General HospitalPark Ridge, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Illinois CancerCare-PekinPekin, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Capital Health Medical Center-HopewellPennington, United StatesNo longer taking part
  • Illinois CancerCare-PeoriaPeoria, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Mercy Health - Perrysburg HospitalPerrysburg, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Illinois CancerCare-PeruPeru, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Fox Chase Cancer CenterPhiladelphia, United StatesContact: Angela Jain (principal investigator)Taking people
  • Pennsylvania HospitalPhiladelphia, United StatesContact: Mark S. Diamond (principal investigator)Taking people
  • Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Jennifer M. Johnson (principal investigator)Taking people
  • Mayo Clinic Hospital in ArizonaPhoenix, United StatesNo longer taking part
  • OhioHealth Pickerington Methodist HospitalPickerington, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Adam M. Brufsky (principal investigator)Taking people
  • UPMC-Magee Womens HospitalPittsburgh, United StatesContact: Adam M. Brufsky (principal investigator)Taking people
  • UPMC-Passavant HospitalPittsburgh, United StatesContact: Adam M. Brufsky (principal investigator)Taking people
  • UM Sylvester Comprehensive Cancer Center at PlantationPlantation, United StatesContact: Chukwuemeka (Emeka) V. Ikpeazu (principal investigator)Taking people
  • Michigan Healthcare Professionals PontiacPontiac, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Trinity Health Saint Joseph Mercy Oakland HospitalPontiac, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Oregon Health and Science UniversityPortland, United StatesContact: Christopher W. Ryan (principal investigator)Taking people
  • Providence Portland Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Providence Saint Vincent Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Southern Ohio Medical CenterPortsmouth, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Kootenai Clinic Cancer Services - Post FallsPost Falls, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Illinois CancerCare-PrincetonPrinceton, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Roger Williams Medical CenterProvidence, United StatesContact: Ritesh Rathore (principal investigator)Taking people
  • Women and Infants HospitalProvidence, United StatesContact: Paul A. DiSilvestro (principal investigator)Taking people
  • Aurora Cancer Care-RacineRacine, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Duke Women's Cancer Care RaleighRaleigh, United StatesContact: Angeles A. Secord (principal investigator)Taking people
  • Rapid City Regional HospitalRapid City, United StatesNo longer taking part
  • Corewell Health Reed City HospitalReed City, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Annie Penn Memorial HospitalReidsville, United StatesContact: Vinay K. Gudena (principal investigator)Taking people
  • Renown Regional Medical CenterReno, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • Valley Medical CenterRenton, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • Marshfield Medical Center-Rice LakeRice Lake, United StatesContact: Adedayo A. Onitilo (principal investigator)Taking people
  • Henrico Doctor's HospitalRichmond, United StatesContact: Andrew S. Kennedy (principal investigator)Taking people
  • VCU Massey Cancer Center at Stony PointRichmond, United StatesContact: Andrew Poklepovic (principal investigator)Taking people
  • VCU Massey Comprehensive Cancer CenterRichmond, United StatesContact: Andrew Poklepovic (principal investigator)Taking people
  • Reid HealthRichmond, United StatesNo longer taking part
  • Virginia Cancer InstituteRichmond, United StatesNo longer taking part
  • Carilion Roanoke Memorial HospitalRoanoke, United StatesContact: Andrew Poklepovic (principal investigator)Taking people
  • Mayo Clinic in RochesterRochester, United StatesContact: Aaron S. Mansfield (principal investigator)Taking people
  • Pluta Cancer CenterRochester, United StatesNo longer taking part
  • Mercyhealth Cancer Institute - RockfordRockford, United StatesContact: Mayur Narkhede (principal investigator)Taking people
  • Mercy Cancer Center - RocklinRocklin, United StatesContact: Loretta J. Nastoupil (principal investigator)Taking people
  • Phelps Health Delbert Day Cancer InstituteRolla, United StatesNo longer taking part
  • Corewell Health Children'sRoyal Oak, United StatesContact: Dana Zakalik (principal investigator)Taking people
  • Corewell Health William Beaumont University HospitalRoyal Oak, United StatesContact: Dana Zakalik (principal investigator)Taking people
  • Mercy Cancer Center - SacramentoSacramento, United StatesContact: Loretta J. Nastoupil (principal investigator)Taking people
  • MyMichigan Medical Center SaginawSaginaw, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Oncology Hematology Associates of Saginaw Valley PCSaginaw, United StatesNo longer taking part
  • Corewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Corewell Health Lakeland Hospitals - Saint Joseph HospitalSaint Joseph, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Heartland Regional Medical CenterSaint Joseph, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • Park Nicollet Clinic - Saint Louis ParkSaint Louis Park, United StatesContact: David M. King (principal investigator)Taking people
  • Regions HospitalSaint Paul, United StatesContact: David M. King (principal investigator)Taking people
  • United HospitalSaint Paul, United StatesContact: David M. King (principal investigator)Taking people
  • Sainte Genevieve County Memorial HospitalSainte Genevieve, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Sharp Memorial HospitalSan Diego, United StatesContact: Charles H. Redfern (principal investigator)Taking people
  • UC San Diego Medical Center - HillcrestSan Diego, United StatesContact: Peter Vu (principal investigator)Taking people
  • UCSF Medical Center-Mission BaySan Francisco, United StatesNo longer taking part
  • Kootenai Clinic Cancer Services - SandpointSandpoint, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Essentia Health SandstoneSandstone, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Saint John's Cancer InstituteSanta Monica, United StatesContact: Reva K. Basho (principal investigator)Taking people
  • Guthrie Medical Group PC-Robert Packer HospitalSayre, United StatesContact: Joyson Poulose (principal investigator)Taking people
  • MaineHealth Maine Medical Center- ScarboroughScarborough, United StatesContact: Leslie S. Bradford (principal investigator)Taking people
  • Swedish Medical Center-First HillSeattle, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Prisma Health Cancer Institute - SenecaSeneca, United StatesContact: Ki Y. Chung (principal investigator)Taking people
  • Sidney Kimmel Cancer Center Washington TownshipSewell, United StatesContact: Jennifer M. Johnson (principal investigator)Taking people
  • ThedaCare Cancer Care - ShawanoShawano, United StatesContact: Matthias Weiss (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at SheboyganSheboygan, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Sheboygan Physicians GroupSheboygan, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Vince Lombardi Cancer Clinic-SheboyganSheboygan, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Memorial Hospital EastShiloh, United StatesContact: Nusayba Bagegni (principal investigator)Taking people
  • Sanford Cancer Center Oncology ClinicSioux Falls, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Sanford USD Medical Center - Sioux FallsSioux Falls, United StatesContact: Daniel Almquist (principal investigator)Taking people
  • Robert Wood Johnson University Hospital SomersetSomerville, United StatesContact: Patrick M. Boland (principal investigator)Taking people
  • Memorial Hospital of South BendSouth Bend, United StatesNo longer taking part
  • VCU Community Memorial Health CenterSouth Hill, United StatesContact: Andrew Poklepovic (principal investigator)Taking people
  • MaineHealth Cancer Care and IV Therapy - South PortlandSouth Portland, United StatesContact: Leslie S. Bradford (principal investigator)Taking people
  • Baptist Memorial Hospital and Cancer Center-DesotoSouthhaven, United StatesContact: Andrew J. Benefield (principal investigator)Taking people
  • Baystate Medical CenterSpringfield, United StatesContact: Tashanna K. Myers (principal investigator)Taking people
  • CoxHealth South HospitalSpringfield, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • Mercy Hospital SpringfieldSpringfield, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • Southern Illinois University School of MedicineSpringfield, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Springfield ClinicSpringfield, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Springfield Memorial HospitalSpringfield, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Springfield Regional Cancer CenterSpringfield, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Springfield Regional Medical CenterSpringfield, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Mercy Hospital Saint LouisSt Louis, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • Mercy Hospital SouthSt Louis, United StatesContact: Jay W. Carlson (principal investigator)Taking people
  • Missouri Baptist Medical CenterSt Louis, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Siteman Cancer Center at Christian HospitalSt Louis, United StatesContact: Nusayba Bagegni (principal investigator)Taking people
  • Siteman Cancer Center-South CountySt Louis, United StatesContact: Nusayba Bagegni (principal investigator)Taking people
  • Washington University School of MedicineSt Louis, United StatesContact: Nusayba Bagegni (principal investigator)Taking people
  • Marshfield Medical Center-River Region at Stevens PointStevens Point, United StatesContact: Adedayo A. Onitilo (principal investigator)Taking people
  • Tufts Medical Center Cancer Center StonehamStoneham, United StatesContact: Francis W. Nugent (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Houston Methodist Sugar Land HospitalSugar Land, United StatesNo longer taking part
  • Missouri Baptist Sullivan HospitalSullivan, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Aurora Medical Center in SummitSummit, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • State University of New York Upstate Medical UniversitySyracuse, United StatesContact: Mary J. Cunningham (principal investigator)Taking people
  • MyMichigan Medical Center TawasTawas City, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Scott and White Memorial HospitalTemple, United StatesContact: Lucas Wong (principal investigator)Taking people
  • Montefiore Medical Center - Moses CampusThe Bronx, United StatesContact: Balazs Halmos (principal investigator)Taking people
  • Montefiore Medical Center-Einstein CampusThe Bronx, United StatesContact: Balazs Halmos (principal investigator)Taking people
  • Montefiore Medical Center-Weiler HospitalThe Bronx, United StatesContact: Balazs Halmos (principal investigator)Taking people
  • Houston Methodist The Woodlands HospitalThe Woodlands, United StatesNo longer taking part
  • Mercy Health - Saint Anne HospitalToledo, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Toledo Clinic Cancer Centers-ToledoToledo, United StatesNo longer taking part
  • Community Medical CenterToms River, United StatesContact: Patrick M. Boland (principal investigator)Taking people
  • Munson Medical CenterTraverse City, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • Corewell Health Beaumont Troy HospitalTroy, United StatesContact: Dana Zakalik (principal investigator)Taking people
  • Upper Valley Medical CenterTroy, United StatesContact: Tarek M. Sabagh (principal investigator)Taking people
  • Saint Luke's Cancer Institute - Twin FallsTwin Falls, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Vince Lombardi Cancer Clinic-Two RiversTwo Rivers, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Carle Cancer CenterUrbana, United StatesContact: Tanmay Sahai (principal investigator)Taking people
  • Essentia Health Virginia ClinicVirginia, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Providence Saint Mary Regional Cancer CenterWalla Walla, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Epic Care Cyberknife CenterWalnut Creek, United StatesNo longer taking part
  • Northwestern Medicine Cancer Center WarrenvilleWarrenville, United StatesContact: Devalingam Mahalingam (principal investigator)Taking people
  • Illinois CancerCare - WashingtonWashington, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Waukee ClinicWaukee, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • UW Cancer Center at ProHealth CareWaukesha, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • ThedaCare Cancer Care - WaupacaWaupaca, United StatesContact: Matthias Weiss (principal investigator)Taking people
  • Aurora Cancer Care-Milwaukee WestWauwatosa, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Aurora West Allis Medical CenterWest Allis, United StatesContact: Antony Ruggeri (principal investigator)Taking people
  • Saint Mary's Oncology/Hematology Associates of West BranchWest Branch, United StatesNo longer taking part
  • OhioHealth Westerville Medical Campus/Westerville Cancer CenterWesterville, United StatesContact: Aine E. Clements (principal investigator)Taking people
  • Saint Ann's HospitalWesterville, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Marshfield Medical Center - WestonWeston, United StatesContact: Adedayo A. Onitilo (principal investigator)Taking people
  • Presbyterian Intercommunity HospitalWhittier, United StatesNo longer taking part
  • Asplundh Cancer PavilionWillow Grove, United StatesContact: Jennifer M. Johnson (principal investigator)Taking people
  • Wake Forest University Health SciencesWinston-Salem, United StatesContact: Anna Kuan-Celarier (principal investigator)Taking people
  • Woodland Memorial HospitalWoodland, United StatesContact: Loretta J. Nastoupil (principal investigator)Taking people
  • Lankenau Medical CenterWynnewood, United StatesContact: Paul B. Gilman (principal investigator)Taking people
  • University of Michigan Health - WestWyoming, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
  • North Star Lodge Cancer Center at Yakima Valley Memorial HospitalYakima, United StatesContact: Khawaja S. Jahangir (principal investigator)Taking people
  • Saint Elizabeth Youngstown HospitalYoungstown, United StatesNo longer taking part
  • Huron Gastroenterology PCYpsilanti, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
  • Genesis Healthcare System Cancer Care CenterZanesville, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
  • Midwestern Regional Medical CenterZion, United StatesNo longer taking part

About the trial

What the trial wants to find out

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

The 20 groups in the trial

  • EAY191-A2 (Cohort 1, Arm A)Treatment being tested

    Cohort 1, Arm A: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.

    Treatment: Alpelisib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, and Positron Emission Tomography

  • EAY191-A2 (Cohort 2, Arm B)Treatment being tested

    Cohort 2, Arm B: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.

    Treatment: Alpelisib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, and Positron Emission Tomography

  • EAY191-A2 (Cohort 2, Arm C)Treatment being tested

    Cohort 2, Arm C: Patients receive olaparib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients experiencing disease progression have the option to migrate to Cohort 3, Arm D. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.

    Treatment: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, and Positron Emission Tomography

  • EAY191-A2 (Cohort 3, Arm D)Treatment being tested

    Cohort 3, Arm D: Patients receive olaparib PO BID and alpelisib PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 5 years in the absence of disease progression, unacceptable toxicity, or bone marrow findings consistent with MDS or AML. Patients also undergo MRI, CT, and/or PET scans throughout the trial and a biopsy prior to treatment start. Patients may also undergo bone scans on study as clinically indicated. Patients have the option to also undergo blood collection throughout the trial and a second biopsy at time of disease progression.

    Treatment: Alpelisib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Olaparib, and Positron Emission Tomography

  • EAY191-A3 Combo Cohorts 1, 2, 3, 4 (palbociclib, binimetinib)Treatment being tested

    Patients receive palbociclib PO and binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.

    Treatment: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, and Palbociclib

  • EAY191-A3 Monotherapy Cohort 1 (binimetinib)Treatment being tested

    Patients receive binimetinib PO throughout the trial. Patients may also undergo biopsy at screening and undergo MRI, CT, bone scan, and collection of blood samples during screening, on study, and/or during follow up.

    Treatment: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, and Magnetic Resonance Imaging

  • EAY191-A6 Arm I (RAS/RAF/MEK/ERK mutations)Treatment being tested

    Patients receive leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or a FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated.

    Treatment: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Oxaliplatin, and Positron Emission Tomography

  • EAY191-A6 Arm II (RAS/RAF/MEK/ERK mutations)Treatment being tested

    Patients receive binimetinib PO, leucovorin IV, oxaliplatin IV, and fluorouracil IV on study. Patients undergo ECHO and MUGA during screening and on study, a CT with contrast, MRI, or an FDG-PET during screening, collection of blood during screening and on study, and a biopsy during screening. Patients may also undergo brain MRI or CT during screening and on study, bone scans on study, and biopsy on study if clinically indicated

    Treatment: Binimetinib, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Oxaliplatin, and Positron Emission Tomography

  • EAY191-E4 (taxane therapy)Treatment being tested

    Patients receive nilotinib hydrochloride monohydrate PO BID on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI during screening or cycle 1 day 1, every 2 cycles for 1 year, every 3 cycles for patients on study for more than 1 year, and every 4 cycles for patients on study for more than 3 years and may also undergo CT or MRI during follow-up every 3 months for 2 years and then every 6 months for 1 year if clinically indicated. Patients also undergo collection of blood samples at baseline, cycle 2 day 1, and optionally at progression as well as tumor biopsy at baseline and optionally at progression.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nilotinib Hydrochloride Monohydrate, and Paclitaxel

  • EAY191-E5 Cohort I Arm A (sotorasib, panitumumab)Treatment being tested

    Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, and Sotorasib

  • EAY191-E5 Cohort I Arm B (sotorasib)Existing treatment, for comparison

    Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, and Sotorasib

  • EAY191-E5 Cohort II (sotorasib)Treatment being tested

    Patients receive combination therapy as in EAY191-E5 Arm A.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, and Sotorasib

  • EAY191-N2 Cohort I (Arm I) (NF1 mutations)Treatment being tested

    Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles and binimetinib PO BID on days 15 to 28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT, MRI, or bone scan, ECHO or MUGA, and tumor biopsy, as well as possible blood sample collection during screening and on study.

    Treatment: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, and Multigated Acquisition Scan

  • EAY191-N2 Cohort I (Arm II) (NF1 mutations)Treatment being tested

    Patients receive fulvestrant IM on day 1 and day 15 of cycle 1 and day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress on fulvestrant alone may migrate to cohort II if they meet the migration eligibility criteria. Patients not willing to migrate to cohort II will have further therapy at the investigator's discretion. Patients undergo a CT, MRI, or bone scan and tumor biopsy, as well as ECHO or MUGA and possible blood sample collection during screening and on study.

    Treatment: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, and Multigated Acquisition Scan

  • EAY191-N2 Cohort II (NF1 mutations)Treatment being tested

    Patients receive fulvestrant IM on day 1 of each cycle and binimetinib PO BID on days 15-28 of cycle 1 and day 1 through 28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT, MRI, or bone scan, ECHO or MUGA and tumor biopsy, as well as possible blood sample collection during screening and on study.

    Treatment: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, and Multigated Acquisition Scan

  • EAY191-N4 Arm I (RAS pathway mutations)Treatment being tested

    Patients receive selumetinib PO BID and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.

    Treatment: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Mutation Carrier Screening, Olaparib, and Selumetinib Sulfate

  • EAY191-N4 Arm II (RAS pathway mutations)Existing treatment, for comparison

    Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.

    Treatment: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Mutation Carrier Screening, and Selumetinib Sulfate

  • EAY191-N5 Arm I (neratinib maleate)Existing treatment, for comparison

    Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, and Neratinib Maleate

  • EAY191-N5 Arm II (neratinib maleate,palbociclib)Treatment being tested

    Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Neratinib Maleate, and Palbociclib

  • EAY191-S3 (activating AKT mutation)Treatment being tested

    Patients receive paclitaxel IV on days 1, 8, and 15 and ipatasertib PO on days 1-21 of each cycle. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and optionally during follow-up.

    Treatment: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, and Paclitaxel

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Plain-language title
Tumor gene screening to assign drug combinations in advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 November 2026